The general mode of action of the mAbXcite technology is outlined below:
MabXcite binds to tumor antigen and presents beta-1,6 glucan on surface of tumor
Endogenous anti-fungal antibodies detect beta-1,6-glucan
The anti fungal antibodies trigger an innate immune response, which is initiated through complement
Complement attracts neutrophils and other components of the innate immune response to destroy the tumor
The presence of neutrophils and destruction of the tumor leads to an adaptive immune response which limits future tumor growth and metastasis
While the field of immuno-oncology has historically focused on the adaptive immune system, ImmuneXcite is executing a targeted approach that leverages the power of the body’s innate and adaptive immune systems in pursuit of effective treatments for cancer.
ImmuneXcite’s product platform is based on discoveries which identified a unique fungal carbohydrate responsible for stimulating the innate immune system—the immune system’s first response against fungal infections. These carbohydrates are covalently attached to tumor-targeting monoclonal antibodies, which specifically attract complement that then recruits other immune cells, such as neutrophils, to kill tumor cells. This innate immune response subsequently primes the natural adaptive immune response to further limit tumor growth and metastasis.